Elias Zerhouni Quotations

It is the responsibility of those of us involved in today's biomedical research enterprise to translate the remarkable scientific innovations we are witnessing into health gains for the nation. At no other time has the need for a robust, bidirectional information flow between basic and translational scientists been so necessary.

Last but not least, I would say you should have big dreams, full dreams, not half dreams. You know, it's very simple. You can't put a large box in a small box. Well, you cannot put a full life in a small dream box.

NIH is doing what it does best -- caring for the sickest of the sick. Our disease specialists and hospital staff are partnering with medical centers around the country to give expert advice and care to hurricane victims with the most challenging medical conditions.

NIH is doing what it does best -- caring for the sickest of the sick, ... Our disease specialists and hospital staff are partnering with medical centers around the country to give expert advice and care to hurricane victims with the most challenging medical conditions.

This resource will enable us to fully analyze, characterize and control the quality of approved cell lines.

There is a definite willingness to be completely co-operative, be completely transparent and to exchange samples with the WHO and with other partners so we can track the genetic changes.

We have a balanced set of conflict of interest rules that protect the integrity of NIH and its ability to provide the American public with an unbiased and trusted source of scientific and health information, while preserving our ability to recruit and retain world class scientists and staff.

We look like we're just crybabies, ... And the world out there is not sympathetic to government scientists who make more money than the vice president of the United States. Let's get real.

These rules are the most restrictive of any rules we know about in the world of biomedical research, ... The rules as you see them today are extremely stringent. With the ban on consulting for paid activities, I think Congress should be very fully reassured we've addressed the fundamental issue of public trust in the integrity of the science.

This atlas of genomic changes will provide new insights into the biological basis of cancer, which in turn will lead to new tests to detect cancer in its early, most treatable stages; new therapies to target cancer at its most vulnerable points; and, ultimately, new strategies to prevent cancer.

This initiative would not have been possible a year or two ago. This is a tangible result of the nation's increased investment in medical research over the past ten years. . . . We stand on the threshold of creating a future that will revolutionize the practice of medicine by allowing us to predict disease, develop more precise therapies and, ultimately, preempt the development of disease in the first place.

The issues that we were facing were not related to stock holdings in great part, ... Therefore, this is where I convinced myself it was not necessary to have a blanket divestiture rule.